Navigation Links
PBS-Bio uncovers how Unibioscreen drug kills cancer
Date:3/9/2011

MESA, Ariz. March 8, 2011 Predictive Biomarker Sciences (PBS-Bio) has uncovered how the experimental drug UNBS1450, produced by Unibioscreen, kills cancer cells.

Previous studies have shown that over-activity of a gene known as MCL1 can cause cancer cells to grow out of control. PBS-Bio, which is owned in part by the non-profit, Phoenix-based Translational Genomics Research Institute (TGen), co-discovered that UNBS1450 effectively shuts off the gene and induces apoptosis, the cancer cell's normal process of cellular death.

"It's a very nice candidate drug," said Dr. Michael Bittner, a biologist and Principal Investigator of the PBS-Bio technology. Dr. Bittner said UNBS1450 is effective against MCL1 in very low dosages, which means it could potentially be delivered to patients with minimal side effects and low toxicity. MCL1 is prevalent in leukemia, non-small-cell lung cancer, as well as cancers of the prostate and pancreas.

"The presence of MCL1 can be used as a stratification, or predictive, biomarker to help determine which cancer patients are most likely to respond to UNBS1450," said Dr. Edward Smith, co-founder and CEO of PBS-Bio. This would be particularly beneficial, Dr. Smith said, in selecting patients to participate in clinical trials of UNBS1450, and ultimately in helping physicians decide who should be placed on the drug once it is approved for general use.

Steve Weitman, Chief Medical Officer for Unibioscreen, based in Brussels, Belgium, said Unibioscreen has high hopes for the drug UNBS1450.

"Thanks to the critical assistance we received from PBS-Bio, we at Unibioscreen feel confident now that we have a potential biomarker that can be used to facilitate the development of UNBS1450," Weitman said.

In October, Unibioscreen announced it had entered into an agreement with PBS-Bio to get a more in depth understanding of the mechanisms involved in UNBS1450 as a means of optimizing cancer-patient treatment.

To jump-start drug development, PBS-Bio's analysis helps pharmaceutical companies better understand how their drugs work, and identifies biomarkers that can help predict which patients will respond to treatment.

PBS-Bio is providing drug companies with unique real-time looks at how new therapeutics actually work over time within cellular pathways the so-called mechanisms of action.

UNBS1450 has been in Phase I clinical trials at hospitals in Belgium and the Netherlands. The drug is a hemi-synthetic derivative of a compound identified by Unibioscreen in the root bark of a plant called Calotropis procera. Pre-clinical tests showed that UNBS1450 is very effective against various tumor types with no adverse side effects.


'/>"/>

Contact: Dr. Edward Smith
edsmith@pbs-bio.com
602-418-9300
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. TGen partner, PBS-Bio, makes first breakthrough drug analysis
2. Georgia Dentist Uncovers Obscure Law That Helps Dental Patients With Severe Anxiety
3. New Research Uncovers Elusive Target of Antifungal Agent
4. Purdue-IU team uncovers potential prostate cancer marker
5. Research uncovers extensive natural recovery after spinal cord injury
6. UCLA team uncovers mechanism behind organ transplant rejection
7. Quest for designer bacteria uncovers a Spy
8. Research uncovers a secret society connecting through the Internet
9. Research Uncovers Clue to SIDS
10. New York Truck Driver Watching Porn Kills Mother, Appalls Personal Injury Lawyers Such As David Perecman
11. Cognitive Skills May Shrink With Tamoxifen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... Successful recruitment and retention efforts, ... scientific initiatives have all marked the last 12 months at Roswell Park Cancer ... the nation’s oldest cancer center, Candace S. Johnson, PhD, outlined the many accomplishments ...
(Date:2/5/2016)... ... February 05, 2016 , ... Looking for a last-minute Valentine’s Day ... tips of your toes. Foot massage, whether administered by a professional masseuse or a ... The American Board of Multiple Specialties in Podiatry (ABMSP) has taken the ...
(Date:2/5/2016)... ... ... US Sports Camps , official operators of Nike Yoga Camps, announces ... training. ChildLight Yoga Studio is centrally situated in the picturesque New England city of ... founder Lisa Flynn expresses her excitement, “We are thrilled to be partnering with US ...
(Date:2/5/2016)... ... 2016 , ... Give To Cure today announced that it is ... Give To Cure’s campaign that is crowdfunding clinical trials to help find cures faster ... through a smart device. In 2015 alone, Venmo processed $7.5 billion in transactions among ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. Justin Scott and Dr. ... Annual No Cost Dental Day to individuals in need. The event is scheduled to ... No Cost Dental Day is to provide dental care to community members in need. ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... -- For hospitals considering enrollment in the Federal 340B ... program, the Health Resources and Services Administration,s (HRSA) recent ... , could have significant impact on plans and operations, ... Essential Insights , Daniel Neal, director ... Mega-Guidance,s key proposed changes, including a new requirement that ...
(Date:2/4/2016)... 4, 2016  The Senior Care Pharmacy Coalition ... Committee Chairman Jason Chaffetz (R-UT) and ... hearing , "Developments in the Prescription Drug ... growing questions about abusive pharmacy benefit manager (PBM) ... and Ranking Member Elijah Cummings (D-MD) are diligent, ...
(Date:2/4/2016)...   Bernstein Liebhard LLP today announced that a ... District Court for the District of Arizona ... all persons or entities who purchased common shares of Insys ... from March 3, 2015 through January 25, 2016 (the "Class ... with violations of the Securities Exchange Act of 1934.  ...
Breaking Medicine Technology: